Shea W K, Black J, Ip M M
Grace Cancer Drug Center, Roswell Park Memorial Institute, New York State Department of Health, Buffalo 14263.
Prostate. 1989;15(2):157-70. doi: 10.1002/pros.2990150209.
A model system has been developed that permits short-term culture of rat R3327 prostate adenocarcinoma epithelial cells on a reconstituted basement membrane. Growth of prostate tumor cells under these conditions resulted in an enriched epithelial cell population that exhibited an eightfold increase in cell number in 10 days. This model system was used to test the efficacy of the thiazolidinedione derivative CGP 19984, a drug that inhibits luteinizing hormone secretion in vivo. At concentrations ranging between 1 and 25 micrograms/ml, CGP 19984 inhibited growth of the prostate tumor epithelial cells in a dose-dependent manner. The results thus demonstrate a direct effect of CGP 19984, which complements its indirect antitumor action in vivo, and suggest that this drug might be an effective agent for treatment of prostatic cancer. Moreover, growth of prostate tumor epithelial cells on a reconstituted basement membrane provides a useful system for in vitro testing of drugs for prostate cancer.
已开发出一种模型系统,可使大鼠R3327前列腺腺癌上皮细胞在重组基底膜上进行短期培养。在这些条件下前列腺肿瘤细胞的生长导致上皮细胞群体富集,细胞数量在10天内增加了八倍。该模型系统用于测试噻唑烷二酮衍生物CGP 19984的功效,该药物在体内可抑制促黄体生成素分泌。在浓度为1至25微克/毫升的范围内,CGP 19984以剂量依赖的方式抑制前列腺肿瘤上皮细胞的生长。因此,结果证明了CGP 19984的直接作用,这补充了其在体内的间接抗肿瘤作用,并表明该药物可能是治疗前列腺癌的有效药物。此外,前列腺肿瘤上皮细胞在重组基底膜上的生长为前列腺癌药物的体外测试提供了一个有用的系统。